Alemtuzumab and intrathecal methotrexate failed in the therapy of Rasmussen encephalitis

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10373632" target="_blank" >RIV/00216208:11130/17:10373632 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/17:10373632
Result on the web
<a href="https://doi.org/10.1212/NXI.0000000000000354" target="_blank" >https://doi.org/10.1212/NXI.0000000000000354</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1212/NXI.0000000000000354" target="_blank" >10.1212/NXI.0000000000000354</a>

Result language
angličtina
Original language name
Alemtuzumab and intrathecal methotrexate failed in the therapy of Rasmussen encephalitis
Original language description
Rasmussen encephalitis (RE) is a rare but devastating unihemispheric brain disorder that often affects children. The clinical picture is characterized by intractable focal epilepsy and progressive decline of functions associated with the affected hemisphere.2 Despite its known inflammatory background and T-cell involvement, immunotherapy appears to slow rather than halt disease progression, and hemispherotomy appears to be the only solution for intractable epilepsy. A potential early therapeutic window has been suggested, and new therapeutic agents have become available.1 A monoclonal antibody targeting CD52 that leads to long-term depletion of lymphocytes (alemtuzumab) has previously been considered as a possible treatment option for RE, but clinical data are limited.
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)